OKYO Pharma (OKYO) Competitors $2.35 +0.07 (+3.07%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.28 -0.08 (-3.19%) As of 08/29/2025 05:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OKYO vs. ADCT, ALDX, FULC, CGC, BNTC, CTMX, CADL, AMRN, LRMR, and DRUGShould you be buying OKYO Pharma stock or one of its competitors? The main competitors of OKYO Pharma include ADC Therapeutics (ADCT), Aldeyra Therapeutics (ALDX), Fulcrum Therapeutics (FULC), Canopy Growth (CGC), Benitec Biopharma (BNTC), CytomX Therapeutics (CTMX), Candel Therapeutics (CADL), Amarin (AMRN), Larimar Therapeutics (LRMR), and Bright Minds Biosciences (DRUG). These companies are all part of the "pharmaceutical products" industry. OKYO Pharma vs. Its Competitors ADC Therapeutics Aldeyra Therapeutics Fulcrum Therapeutics Canopy Growth Benitec Biopharma CytomX Therapeutics Candel Therapeutics Amarin Larimar Therapeutics Bright Minds Biosciences ADC Therapeutics (NYSE:ADCT) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability. Is ADCT or OKYO more profitable? OKYO Pharma has a net margin of 0.00% compared to ADC Therapeutics' net margin of -220.00%. Company Net Margins Return on Equity Return on Assets ADC Therapeutics-220.00% N/A -53.73% OKYO Pharma N/A N/A N/A Do institutionals & insiders hold more shares of ADCT or OKYO? 41.1% of ADC Therapeutics shares are held by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are held by institutional investors. 5.4% of ADC Therapeutics shares are held by company insiders. Comparatively, 40.5% of OKYO Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media favor ADCT or OKYO? In the previous week, ADC Therapeutics and ADC Therapeutics both had 1 articles in the media. OKYO Pharma's average media sentiment score of 1.88 beat ADC Therapeutics' score of 0.00 indicating that OKYO Pharma is being referred to more favorably in the news media. Company Overall Sentiment ADC Therapeutics Neutral OKYO Pharma Very Positive Which has more volatility and risk, ADCT or OKYO? ADC Therapeutics has a beta of 2, suggesting that its share price is 100% more volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of -0.1, suggesting that its share price is 110% less volatile than the S&P 500. Do analysts prefer ADCT or OKYO? ADC Therapeutics currently has a consensus target price of $7.75, suggesting a potential upside of 152.03%. OKYO Pharma has a consensus target price of $7.00, suggesting a potential upside of 197.87%. Given OKYO Pharma's higher probable upside, analysts plainly believe OKYO Pharma is more favorable than ADC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ADC Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00OKYO Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings & valuation, ADCT or OKYO? OKYO Pharma has lower revenue, but higher earnings than ADC Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioADC Therapeutics$77.25M4.48-$157.85M-$1.57-1.96OKYO PharmaN/AN/A-$4.71MN/AN/A SummaryOKYO Pharma beats ADC Therapeutics on 6 of the 10 factors compared between the two stocks. Get OKYO Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for OKYO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OKYO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OKYO vs. The Competition Export to ExcelMetricOKYO PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$88.38M$3.08B$5.69B$9.74BDividend YieldN/A2.28%6.66%4.48%P/E RatioN/A20.9283.1926.59Price / SalesN/A352.35515.16159.17Price / CashN/A43.5325.6628.92Price / Book-14.699.7811.766.08Net Income-$4.71M-$54.01M$3.27B$265.93M7 Day Performance-3.29%0.10%1.13%0.36%1 Month Performance-24.19%8.52%8.30%5.58%1 Year Performance95.83%7.03%62.26%19.67% OKYO Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OKYOOKYO Pharma3.0485 of 5 stars$2.35+3.1%$7.00+197.9%+95.8%$88.38MN/A0.007Positive NewsADCTADC Therapeutics1.2762 of 5 stars$3.17+2.6%$7.75+144.5%+6.0%$356.62M$77.25M-2.02310ALDXAldeyra Therapeutics1.8054 of 5 stars$5.89+2.1%$9.50+61.3%+1.5%$352.81MN/A-6.9310FULCFulcrum Therapeutics0.9201 of 5 stars$6.52+1.7%$7.57+16.1%-24.2%$352.68MN/A-5.34100High Trading VolumeCGCCanopy Growth0.5885 of 5 stars$1.47+2.1%N/A-65.5%$352.58M$274.92M-0.493,150Gap DownHigh Trading VolumeBNTCBenitec Biopharma1.5449 of 5 stars$12.76-3.4%$26.00+103.8%+43.2%$334.95M$80K-8.4520Positive NewsCTMXCytomX Therapeutics4.1888 of 5 stars$2.03+1.5%$5.75+183.3%+72.9%$334.77M$138.10M3.63170CADLCandel Therapeutics2.574 of 5 stars$5.96+4.4%$22.00+269.1%-14.2%$327.20M$120K-8.6460AMRNAmarin0.2141 of 5 stars$15.54+1.0%$12.00-22.8%+20.2%$321.79M$219.36M-4.23360LRMRLarimar Therapeutics2.4552 of 5 stars$3.87+4.0%$18.43+376.2%-54.2%$320.35MN/A-2.4830Positive NewsDRUGBright Minds Biosciences2.4169 of 5 stars$44.77+7.4%$83.25+86.0%+3,567.9%$315.18MN/A-48.14N/APositive News Related Companies and Tools Related Companies ADCT Alternatives ALDX Alternatives FULC Alternatives CGC Alternatives BNTC Alternatives CTMX Alternatives CADL Alternatives AMRN Alternatives LRMR Alternatives DRUG Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OKYO) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredA Major Economic Change Is Happening NowLouis Navellier is one of Wall Street’s most respected money managers — overseeing more than $7 billion and ea...InvestorPlace | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OKYO Pharma Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share OKYO Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OKYO Stock Alerts